1 2 2	Detection of SARS-CoV-2 antibodies formed in response to the BNT162b2 and mRNA- 1237 mRNA vaccine by commercial antibody tests					
3 4	Running title: Detection of mRNA vaccine induced SARS-CoV-2 IgG antibodies					
5 6 7 8 9	Jamil N Kanji, MD, DTMH&H, FRCP(C) <sup>a-c,*</sup> , <sup>#</sup> Ashley Bailey, MLS <sup>b</sup> , Jayne Fenton, MLT <sup>b</sup> Sean H Ling, MB, BCh, BAO, MSc <sup>b</sup> , Rafael Rivera <sup>d</sup> , Sabrina Plitt, PhD <sup>d,e</sup> , Wendy I Sligl, MD, MSc, FRCP(C) <sup>a,f</sup> , Sean Taylor, PhD <sup>g</sup> , LeeAnn Turnbull, MLT <sup>b</sup> , Graham Tipples, PhD, FCCM, D(ABMM) <sup>b,h,i</sup> , Carmen L. Charlton, PhD, FCCM, D(ABMM) <sup>b,c,h</sup>					
10 11 12	Affiliations:					
13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31	<ul> <li>a. Division of Infectious Diseases, Department of Medicine, University of Alberta, 8440 – 112 Street NW, Edmonton, AB, T6G 2B7, Canada</li> <li>b. Public Health Laboratory, Alberta Precision Laboratories, University of Alberta Hospital, University of Alberta Hospital, 8440 – 112 Street NW, Edmonton, AB T6G 2B7, Canada</li> <li>c. Department of Laboratory Medicine &amp; Pathology, Faculty of Medicine and Dentistry, University of Alberta Hospital, 8440 – 112 Street NW, Edmonton, AB, T6G 2B7, Canada</li> <li>d. School of Public Health, University of Alberta, 3-003 Edmonton Clinic Health Academy, 11405-87 Avenue NW, Edmonton, AB, T6G 1C9, Canada</li> <li>e. Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, Ottawa, ON, K1A 0K9, Canada</li> <li>f. Department of Critical Care Medicine, University of Alberta, 8440 – 112 Street NW, Edmonton, AB T6G 2B7, Canada</li> <li>g. GenScript USA Inc, 860 Centennial Avenue, Piscataway, NJ 08854, USA</li> <li>h. Li Ka Shing Institute of Virology, University of Alberta, 6-010 Katz Group Centre for Pharmacy and Health Research, Edmonton, AB, T6G 2E1, Canada</li> <li>i. Department of Medical Microbiology and Immunology, Faculty of Medicine and Dentistry, University of Alberta, 8440 – 112 Street NW, Edmonton, AB, T6G 2B7, Canada</li> </ul>					
32 33 34 35 36 37	Canada Word count: Abstract – 250 Manuscript (excluding methods, tables/graphics/references): 2496					
38 39 40 41 42 43 44 45 46 47	<ul> <li>#Corresponding author:</li> <li>Jamil N. Kanji, MD, DTM&amp;H, FRCP(C)</li> <li>Public Health Laboratory, Alberta Precision Laboratories</li> <li>Foothills Medical Centre</li> <li>3030 Hospital Drive NW, Calgary, AB, T2N 4W4</li> <li>Phone: +1 403 944 1200; Fax: +1 403 270 2216</li> <li>Email: jamil.kanji@ahs.ca</li> <li>*Dr. Jamil N. Kanji is now with the Division of Infectious Diseases, Department of</li> <li>Medicine, University of Calgary and with the Public Health Laboratory (Alberta Precision</li> </ul>					
48 49	Laboratories) at the Foothills Medical Centre, 3030 Hospital Drive NW, Calgary, AB, T2N 4W4, Canada.					

49 4W4, Canada.

#### 50 ABSTRACT

#### 51 PURPOSE

- 52 With rapid approval of SARS-CoV-2 vaccines, the ability of clinical laboratories to detect
- 53 vaccine-induced antibodies with available high-throughput commercial assays is unknown.
- 54 We aimed to determine if commercial serology assays can detect vaccine-induced antibodies
- 55 (VIAs) and understand the vaccination response.

# 56 METHODS

- 57 This cohort study recruited healthcare workers and residents of long-term care facilities
- 58 (receiving the BNT162b2 and mRNA-1273 products, respectively) who underwent serum
- 59 collection pre-vaccination (BNT162b2 group), 2-weeks post vaccination (both groups), and
- 60 pre-2<sup>nd</sup> dose (both groups). Sera were tested for the presence of SARS-CoV-2 IgG using four
- 61 commercial assays (Abbott Architect SARS-CoV-2 IgG, Abbott Architect SARS-CoV-2 IgG
- 62 II Quant, DiaSorin Liaison Trimeric S IgG, and GenScript cPASS) to detect VIAs.
- 63 Secondary outcomes included description of post-vaccination antibody response and
- 64 correlation with neutralising titers.

65 RESULTS

- 66 225 participants (177 receiving BNT162b2 and 48 receiving mRNA-1273) were included
- 67 (median age 41 years,; 66-78% female). Nucleocapsid IgG was found in 4.1% and 21.9% of
- the BNT162b2 (baseline) and mRNA-1273 (2-weeks post first dose). All anti-spike assays
- detected antibodies post-vaccination, with an average increase of 87.2% (range 73.8-94.3%;
- 70 BNT162b2), and 25.2% (range 23.8-26.7%; mRNA-1273) between the first and last sampling
- 71 time points (all p<0.05). Neutralising antibodies were detected at all post-vaccine timepoints
- for both vaccine arms, with increasing titers over time (all p < 0.05).

# 73 CONCLUSION

- 74 Anti-spike vaccine-induced SARS-CoV-2 IgG are detectable by commercially available
- 75 high-throughput assays and increases over time. Prior to second dose of vaccination,
- neutralising antibodies are detectable in 73-89% of individuals, suggesting the majority of
- 77 individuals would have some degree of protection from subsequent infection.
- 78
- 79 Key words:
- 80 SARS-CoV-2, neutralising antibodies, commercial assays, mRNA vaccine, mRNA-1273,
- 81 BNT162b2, spike protein, receptor binding domain, trimeric

# 82 Introduction

83	To date, the principal utility of SARS-CoV-2 IgG high throughput serology assays has been
84	to conduct seroprevalence studies for large cohorts to aid public health decision-making [1,
85	2]. Until recently, all seroprevalence studies have examined detection of antibodies from
86	natural infection. While most vaccine candidates produced detectable antibody levels on
87	specific serological research assays in early phase trials [3-5], it is unclear how currently
88	available high-throughput commercial assays will detect vaccine-induced antibody in the
89	clinical laboratory. In the case of varicella, detection of vaccine-induced antibody is variable
90	among commercial kits compared to detection of antibodies produced from natural infection,
91	which are more robust [6].
92	
93	SARS-CoV-2 neutralization antibodies have been shown to predict disease severity and
94	survival [7]. There is also evidence of their protective capacity in preventing infection in
95	animal models and humans [8-10]. These data corroborate evidence for neutralising antibody
96	(nAb) protection in numerous viral infections including yellow fever, encephalitis, dengue,
97	mumps, influenza and others [11]. To date, there is little data measuring the level of nAbs
98	pre/post-vaccination for SARS-CoV-2 nor how results compare with vaccine efficacy and
99	protection.
100	

Currently approved SARS-CoV-2 vaccines in the United States and Canada (BNT162b2 and
mRNA-1273 products) consist of lipid nanoparticles formulated nucleoside-modified
messenger RNA (mRNA) [12, 13]. Both formulations induce T-cell activation and
production of antibodies in response to *in vivo* production of SARS-CoV-2 spike (S) protein
following translation of the synthetic mRNA in human cells [14]. Antibodies against the

106	receptor binding domain	(RBD	) found in	the S1	region of	of the	spike ge	ene [3.	15	, anti-S1

107 protein IgG [14], as well as neutralising antibody [14, 16] have been detected in response to

- 108 both vaccines.
- 109

110	We aimed to evaluate the abilit	y of three c	commercial S	SARS-CoV-2	IgG ass	says and o	one

- 111 functional nAb test to detect and quantify antibodies in two separate patient populations
- 112 receiving their first doses of the BNT162b2 and mRNA-1273 SARS-CoV-2 mRNA vaccines.
- 113 It was hypothesized that assays targeting non-spike proteins (e.g., nucleocapsid (N) protein)
- 114 would screen positive only in individuals who previously recovered from natural SARS-
- 115 CoV-2 infection. It was further postulated that there could be a difference between the IgG
- 116 binding antibody total immune response versus the nAb response to vaccination.
- 117

## 118 Methods

## 119 Participant sample collection

- 120 Serum samples were collected prospectively from two separate patient groups undergoing
- 121 COVID-19 vaccination. The first group consisted of healthcare workers (HCWs) who
- 122 received the BNT162b2 vaccine series while the second group consisted of residents of long-
- 123 term care facilities who received the mRNA-1273 vaccine series. Herein the groups will be
- 124 referred to as the BNT162b2 and the mRNA-1273 groups, respectively.

- 126 Serum samples in the BNT162b2 group were planned to be drawn at the following
- 127 approximate time points: (i) at baseline (defined as 24-72 hours prior to the first dose, or up
- 128 to five days post the first dose of vaccine), (ii) 14 days post first dose of vaccine; and (iii)

129 within 24 hours of the second dose of vaccine (either the day before, day of, or day prior).

130 Those in the mRNA-1273 group were planned to have samples collected at approximately (i)

131 14 days and (ii) 21-28 days post first dose of vaccine (pre-2<sup>nd</sup> dose). Due to the rapid roll out

132 of vaccine in long-term care facilities, none of the participants in the mRNA-1273 group had

133 baseline/pre-first dose samples collected.

134

### 135 Vaccine distribution

136 Details regarding Alberta COVID-19 vaccine distribution have been outlined previously [17].

137 Briefly, given the need for storage at -70°C, the BNT162b2 vaccine was provided to

138 healthcare workers (those working in areas of intensive care, emergency, care of COVID-19

139 positive patients, and those working in long-term care) at a centralized vaccine depot. The

140 mRNA-1273 product was transported for administration to residents of continuing and long-

141 term care facilities (given ability to store at  $-20^{\circ}$ C) [17]. The two doses of the BNT162b2 and

142 mRNA-1273 products were administered three and four weeks apart, respectively as per

143 vaccine manufacturer recommendations.

144

145 Vaccine administration and allocation was directed as per planned vaccine roll-out by

146 provincial government health authorities and not by the researchers. Inclusion criteria to

147 participate this study comprised being 18 years or older, eligible for and planned COVID-19

148 vaccine series. Participants who had recovered from previous SARS-CoV-2 infection, who

were on biologics or other immunosuppressive medications, or who were pregnant wereincluded.

#### 152 SARS-CoV-2 IgG detection

153	Samples were stored at -20°C and underwent one freeze-thaw cycle prior to testing. Sera
154	were tested for SARS-CoV-2 IgG using three high-throughput commercial assays: Abbott
155	Architect SARS-CoV-2 IgG (IgG targeting the N-protein; qualitative result only) [18],
156	Abbott Architect SARS-CoV-2 IgG II Quant (IgG targeting the RBD-region of the S-protein;
157	quantitative result) [18], and DiaSorin Liaison (trimeric S-protein assay targeting the S1/S2
158	regions of the S-protein; quantitative result) [19]. In addition, we evaluated the presence of
159	SARS-CoV-2 nAbs using the GenScript cPass Neutralisation antibody detection kit (Table
160	S1) [20, 21]. All testing was done according to product inserts and qualitative and
161	quantitative values (where available) were recorded for each assay. Only the assay by
162	GenScript has a claim to detect nAbs.
163	

164 Data analysis

165 Baseline demographics of all participants were extracted from the provincial electronic

166 medical record (EMR) (Table S1). Continuous variables were compared using Mann-

167 Whitney tests while categorical variables were compared using Chi-square or Fisher's exact

- 168 tests. All statistical analysis and graphing were done using Stata version 16.1 (Table S1).
- 169

- 171 Results
- 172 Population demographics
- 173 Serum from 225 participants who received an mRNA COVID-19 vaccine (177 receiving the
- 174 BNT162b2 and 48 receiving mRNA-1273) (Table 1) was collected at up to three timepoints.

175	The median age of all the participants was 41 years (with the mRNA-1273 having a
176	significantly higher median age; 84 vs 37 years). The majority of participants in each group
177	were female (66.7-78.1%). The median time between receipt of vaccine dose 1 and dose 2
178	for both groups was 25-26 days. A significantly higher proportion of mRNA-1273
179	participants had recovered from confirmed SARS-CoV-2 infection (33.3 vs 3.4%). Two
180	participants in the BNT162b2 group were diagnosed with COVID-19 after receipt of their
181	vaccine (one diagnosed seven days after the first dose; the other nine days after the second
182	dose). Medical comorbidities were more commonly seen in the mRNA-1273 group. In total,
183	five participants were being treated with biologics or immunosuppressive medications.
184	
185	Anti-nucleocapsid IgG detection
186	IgG directed towards the SARS-CoV-2 N-protein was found in 3.6-5.4% and 18.9-21.9% of
187	the BNT162b2 and mRNA-1273 groups, respectively (Fig. 1). Over the course of the blood
188	sampling times in each group, the positivity rate for anti-N IgG detection did not change

189 significantly from the baseline to pre- $2^{nd}$  dose sample (*p*=0.86; BNT162b2 group) and from

190 the 2-week and pre- $2^{nd}$  dose samples (*p*=0.76; mRNA-1273 group) in either group.

191 In the BNT162b2 group, all four participants who were COVID-19 recovered prior to their

192 first dose had a detectable anti-N IgG (Table S2). One of four lost their anti-N IgG when

tested two-weeks post first vaccine dose (60 days post diagnosis). 85.7% (6/7) COVID-19

recovered participants in the mRNA-1273 group had detectable anti-N IgG at 2-weeks post

195 first vaccine dose (Table S3) with no detectable anti-N IgG in 44.4% (4/9) participants just

196 prior to receiving their  $2^{nd}$  vaccine dose.

197

198 Anti-Spike IgG and neutralising antibody detection and quantification

### Page 8 of 22

199	The antibody positivity rate for all three S-protein based commercial assays (RBD IgG,
200	Trimeric S IgG, and GenScript nAb) increased on average by 87.2% (range 73.8-94.3%)
201	between baseline and the 2-week samples in the BNT162b2 group, reaching levels of >88%
202	positivity (p<0.0001 for each assay) just prior to the second vaccine dose (Fig. 1). Similarly,
203	large positivity increases between 23.8 and 26.7% were observed between the 2-week post-
204	first dose and pre-2 <sup>nd</sup> dose time points in the mRNA-1273 group with overall increases of
205	>50% and >70% positivity at the two time points respectively, p<0.05 for all comparisons
206	(Table 2). For both time points and with both vaccines the number of participants who were
207	positive for nAbs was significantly lower than those who were positive for IgG binding
208	antibodies by a factor of 10% to 20% (Fig. 1).
209	
210	Quantifiable titers of antibodies detected by each assay were detectable at all time points and
211	increased significantly over time in both vaccine groups (Table 2 and Fig. 2). In the
212	BNT162b2 group, titers increased by 1.8, 1.2, and 1.8-fold for the RBD IgG, Trimeric S IgG,
213	and GenScript nAb assays respectively, from the 2-week blood sampling to the samples
214	drawn just prior to the participants' 2 <sup>nd</sup> dose (with a median number of 11 days between
215	blood draws). Higher-fold titer increases (3.5, 4.1, and 4.5-fold respectively) were seen in the
216	mRNA-1273 participants between blood sampling at similar time points (p=0.06 for RBD
217	IgG and p<0.05 for Trimeric S IgG and nAb assays) (median seven days between blood
218	draws) (Table 2 and Fig. 1). Titer values for a given group and time point were distributed
219	across varying IQRs despite being all classified as positive (Fig. S1).
220	

220

221 Post vaccine testing in special populations

222	Quantitative titres in the mRNA-1273 group were found to be significantly higher among
223	participants who were COVID-19 recovered compared to those with no history of laboratory-
224	confirmed COVID-19 infection (Table S4; $p < 0.001$ for all assays at both time points). This
225	was observed for the two commercial anti-S IgG assays as well as the nAb assay used. This
226	comparison was made only in the mRNA-1273 group given all COVID-19 recovered
227	participants received their first dose of vaccine >14 days from the date of their COVID-19
228	diagnosis.
229	
230	Our sample included a small number of participants (n=5; four from the BNT162b2 group)
231	on biologic or immunosuppressant therapy (Table S5). Four had no evidence of previous
232	COVID-19 infection at baseline. In the group of four (who all received the BNT162b2
233	vaccine), quantitative anti-S IgG/nAb were detected at 2-weeks (4/4) whereas only two
234	samples gave detectable levels of neutralising antibodies and the other two were close to
235	baseline. The absolute values of quantitative titres were comparatively larger for the one
236	participant who was COVID-19 recovered (mRNA-1273 group).
237	

### 238 Discussion

In this study, we demonstrate that vaccine-induced antibodies stimulated by FDA approved SARS-CoV-2 mRNA vaccines (BNT162b2 and mRNA-1273) can be detected by commercial high-throughput assays currently used in clinical laboratories. As predicted, detectable antibody was restricted to assays identifying IgG directed against the viral S-protein, and not against the nucleocapsid protein. Anti-spike vaccine-induced antibodies were detectable as early as ten days following the first dose of an mRNA vaccine. Titres increased significantly over the three-week period from baseline sampling to pre-second dose sampling. Vaccine-

246 induced nAbs targeting the SARS-CoV-2 spike protein were successfully detected, using a 247 surrogate virus neutralization test (sVNT) kit without the use of cell lines and viral culture 248 required for plaque reduction neutralization assays (PRNT) supporting protective immunity 249 [7, 8, 10, 22]. However, there were significantly less participants with detectable nAbs post-250 vaccination as those with a binding antibody IgG response. 251 252 To our knowledge, detection of vaccine-induced antibodies using commercial high-253 throughput SARS-CoV-2 anti-S IgG assays has been limited to a partnership between 254 Roche® and Moderna® demonstrating detection of mRNA-1273 vaccine-induced antibodies 255 using the Elecsys anti-SARS-CoV-2 S test [15] two other studies [23, 24]. Our current study 256 adds to the literature by confirming the detection of these IgG binding and also functional 257 nAbs using commercial kits from other companies likely to be adopted by large volume


- clinical laboratories.
- 259

260 Overall, our data demonstrate significant increases in the median titre of anti-S IgG by all 261 assays evaluated in both mRNA vaccine groups, except for the RBD IgG among the mRNA-262 1273 group which did not measure levels from baseline but only from two weeks post 263 vaccination. Given the lack of an international standard, antibody titres can only be directly 264 compared between successive samples measured on the same assay run [25]. However, when 265 samples from participants in the same vaccine group on the same assay were compared, wide 266 IQRs of titre values were observed (Table 2; Fig. S1). The observed variation is likely 267 multifactorial, and dependant on history of previous SARS-CoV-2 infection, use of 268 immunosuppressive medications, advanced age, and frailty [26]. There is limited data to 269 conclude whether the differing titres in participants in the same group (classified qualitatively 270 as positive), assay, and time-point of sampling, translates to clinical differences in response to

271 infection. For other vaccines, such as hepatitis B and varicella, an initial antibody response 272 following first vaccine dose generally translates into protection from subsequent infection 273 [27, 28]. However, protection is derived from both humoral and cell-mediated responses, of 274 which only humoral is detected by the commercial high throughput EIAs [27, 28]. 275 276 For other viral infections including SARS-CoV-2, there is significant evidence that nAbs are 277 correlated to protection and immunity [7, 11]. Animal challenge studies have provided 278 conclusive evidence for nAb protection to SARS-CoV-2 [22]. nAbs have also been 279 successfully tested in humans to treat the disease [29]. When comparing the prevalence of 280 neutralising and IgG antibodies from SARS-CoV-2 infected and recovered individuals, the 281 prevalence of nAbs was comparable to IgG binding antibodies and to gold standard PRNT 282 [30]. However, we found a significantly lower fraction of participants elicited protective 283 nAbs compared to those with IgG antibodies. A potential explanation is RBD IgG and 284 trimeric S IgG assays measure total binding antibodies, but are unable to differentiate 285 between nAbs and non-nAbs that also bind to the S-protein [31]. Several studies comparing 286 surrogate nAb assays to traditional methods (PRNT) have found them to be effective proxies 287 for detection and quantification of immunodominant nAbs seen in SARS-CoV-2 infection, 288 specifically RBD-targeting nAbs [21, 31] [32]. Encouragingly, at the final study blood draw 289 (pre-second vaccination dose), nAbs were detectable in 73-89% of samples tested from both 290 vaccine groups. Although the prevalence of nAbs remained significantly lower than total 291 binding IgG's, the data support that the majority of individuals would have at least some 292 protection from subsequent infection prior to the second dose, particularly as detection of 293 nAbs has been previously correlated with vaccine efficacy [33, 34]. However, these data 294 underline a cautionary note in that up to 27% of vaccinated individuals did not have

295 protective nAbs prior to the second dose and should remain vigilant in exercising protective 296 public health measures to limit viral spread.

297



- 299 vaccine induced antibody responses and natural infection. Although we found, at baseline, a
- 300 number of COVID-19 recovered participants had detectable anti-N IgG (which would
- 301 confirm previous infection), 30% were undetectable by the pre-second dose blood draw

302 (Table S2 and Table S3). This may be due to a number of factors including, the severity of

303 the initial SARS-CoV-2 infection [35], the specific anti-N IgG assay used [36], the natural

304 decline of N antibodies overtime [37], or possible immune modulation from the vaccine,

305 where the abundance of antibodies produced switched from anti-N following natural

306 infection to anti-S antibodies following vaccination.

307

308 To effectively compare antibody titres (across vaccine groups and assays), a quantitative 309 reference standard and a robust correlation with nAbs is needed for commercial assays to 310 accurately assess the effectiveness of vaccine responses. It will be important for clinical 311 laboratories to identify that vaccine induced antibodies can be detected for each vaccine, and 312 work with public health partners to understand the best use for serological testing. Current 313 guidelines [38, 39] do not recommend clinical serology testing pre or post-vaccination, 314 however these recommendations may change over time with more study. A further 315 understanding of the population-based efficacy and longevity is required to structure 316 recommendations for individualized post-vaccine serology testing in clinical decision 317 making. 318

319	Although sample sizes were low, we observed in the mRNA-1273 group that vaccine-
320	induced antibody responses titres of all three quantitative assays were significantly higher at
321	all time points in participants who recovered from confirmed COVID-19 infection (Table
322	S4). Similar findings have been reported from several other research groups where post-
323	vaccination titres were 10-20 times higher in COVID-19 recovered individuals [40, 41].
324	Furthermore, the responses prior to the second dose of vaccine in COVID-19 recovered
325	participants also exceeded the titres of those from the SARS-CoV-2 naïve participants by 10-
326	fold. This has led to early recommendations by some governments to consider providing
327	only a one-dose primary series in COVID-19 recovered individuals [42].
328	
329	For the four participants on immune suppressive treatment who were not previously SARS-
330	CoV-2 infected, a marked difference between nAb and IgG response to vaccination was
331	observed. Although the participants in this group all produced measurable IgG's two weeks
332	after receiving the first vaccine dose, only two gave measurable nAb levels and the remaining
333	two were just above the detection limit. These data underline the importance of assuring
334	immune protection to SARS-CoV-2 in this highly susceptible subpopulation of
335	immunocompromised individuals.
336	
337	The principal limitation in our findings is that they only demonstrate the production of
338	vaccine-induced antibodies in response to mRNA COVID-19 vaccines and their
339	quantification. Correlations of specific titre levels to protection or vaccine efficacy cannot be
340	made as the study is not designed or powered for this purpose. As the BNT162b2 and
341	mRNA-1273 vaccines are different products, it is difficult to comment on the difference in
342	median titres seen for the same time points on the same assay (which was observed in general
343	to be lower in the mRNA-1273 group, despite a higher proportion of COVID-19 recovered

344	individuals). This may reflect differing median ages of the two groups or alternatively be
345	reflective of responses to varying vaccine products which is an artifact that could be corrected
346	with an international standard for COVID-19 serology.

347

# 348 Conclusions

349	We have shown that currently available commercial assays for detection of anti-spike IgG
350	binding antibodies were successfully able to detect vaccine induced antibodies in the vast
351	majority of vaccinated participants. In general, anti-spike IgG binding antibody titers
352	increased overtime, while anti-nucleocapsid antibodies declined. There was a marked
353	difference in the proportion of participants eliciting protective nAbs for both vaccines and at
354	all time points after the first dose underlining the difference between a general binding IgG
355	and a functional neutralising response correlating to protection. Just prior to the second dose
356	of vaccination, most samples had detectable neutralising antibodies. However, a significant
357	subpopulation did not produce nAbs which underlines the importance of the continued
358	practice of SARS-CoV-2 infection preventive measures after the first vaccine dose at least for
359	those individuals with no detectable levels of nAbs.

360	Declarations
500	Dectarations

- 361
- 362 Research ethics approval
- 363 This study was approved by the Human Research Ethics Board (HREB) at the University of
- 364 Alberta (reference number Pro00106810).

365

- 366 Consent to publication
- 367 Not applicable.

368

- 369 Conflicts of interest/Competing interests
- 370 Sean Taylor is an employee of GenScript USA. He assisted in providing interpretation of the
- 371 GenScript assay used in this study. He had no role in the design of the study or the formal
- 372 data analysis, but did provide suggestions for the final draft which were incorporated after
- 373 review by the other authors. None of the other authors had conflicts to declare with respect to
- this manuscript.

375

376 Funding

- 377 This work did not receive any specific grant from funding agencies in the public, commercial,
- 378 or not-for-profit sectors, however testing kits were provided in-kind by all manufactures.

379

- 380 Availability of data and material
- 381 The datasets used and/or analysed during the current study are available from the
- 382 corresponding author on reasonable request.

## 384 *Authors' contributions*

- 385 Jamil N Kanji Conceptualization, methodology, validation, analysis, data curation, project
- administration, writing original draft, writing review and editing.
- 387 Ashley Bailey validation, investigation, data curation, writing review and editing
- 388 Jayne Fenton investigation, data curation, writing review and editing
- 389 Sean H Ling investigation, data curation, project administration, writing review and
- 390 editing
- 391 Rafael Rivera data curation, formal analysis, writing review and editing
- 392 Sabrina Plitt data curation, formal analysis, project administration, writing review and
- 393 editing
- 394 Wendy I Sligl data curation, investigation, writing review and editing, project
- 395 administration
- 396 Sean Taylor resources, writing review and editing
- 397 LeeAnn Turnbull investigation, writing review and editing
- 398 Graham Tipples project administration, writing review and editing
- 399 Carmen Charlton Conceptualization, methodology, validation, resources, writing original
- 400 draft, writing review and editing, supervision, project administration
- 401
- 402 Acknowledgements
- 403 We would like to thank Abbott Laboratories, DiaSorin and GenScript for providing us with
- 404 complimentary serology testing kits.
- 405

406 ICMJE Criteria

407 All authors attest they meet the ICMJE criteria for authorship.

## 408 **References**

409 410 [1] Van Caeseele P, Bailey D, Forgie SE, Dingle TC, Krajden M (2020) SARS-CoV-2 411 (COVID-19) serology: implications for clinical practice, laboratory medicine and public 412 health. Cmaj 192 (34):E973-e979 413 Rostami A, Sepidarkish M, Leeflang MMG, Riahi SM, Nourollahpour Shiadeh M, [2] 414 Esfandyari S, Mokdad AH, Hotez PJ, Gasser RB (2020) SARS-CoV-2 seroprevalence 415 worldwide: a systematic review and meta-analysis. Clin Microbiol Infect 416 [3] Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, Baum A, 417 Pascal K, Quandt J, Maurus D, Brachtendorf S, Lörks V, Sikorski J, Hilker R, Becker D, 418 Eller A-K, Grützner J, Boesler C, Rosenbaum C, Kühnle M-C, Luxemburger U, Kemmer-419 Brück A, Langer D, Bexon M, Bolte S, Karikó K, Palanche T, Fischer B, Schultz A, Shi P-Y, 420 Fontes-Garfias C, Perez JL, Swanson KA, Loschko J, Scully IL, Cutler M, Kalina W, 421 Kyratsous CA, Cooper D, Dormitzer PR, Jansen KU, Türeci Ö (2020) COVID-19 vaccine 422 BNT162b1 elicits human antibody and TH1 T cell responses. Nature 586 (7830):594-599 423 [4] Barrett JR, Belij-Rammerstorfer S, Dold C, Ewer KJ, Folegatti PM, Gilbride C, 424 Halkerston R, Hill J, Jenkin D, Stockdale L, Verheul MK, Aley PK, Angus B, Bellamy D, 425 Berrie E, Bibi S, Bittaye M, Carroll MW, Cavell B, Clutterbuck EA, Edwards N, Flaxman A, 426 Fuskova M, Gorringe A, Hallis B, Kerridge S, Lawrie AM, Linder A, Liu X, Madhavan M, 427 Makinson R, Mellors J, Minassian A, Moore M, Mujadidi Y, Plested E, Poulton I, Ramasamy 428 MN, Robinson H, Rollier CS, Song R, Snape MD, Tarrant R, Taylor S, Thomas KM, Voysey 429 M, Watson MEE, Wright D, Douglas AD, Green CM, Hill AVS, Lambe T, Gilbert S, Pollard 430 AJ, Aboagye J, Alderson J, Ali A, Allen E, Allen L, Anslow R, Arancibia-Cárcamo CV, 431 Arbe-Barnes EH, Baker M, Baker P, Baker N, Baleanu I, Barnes E, Bates L, Batten A, 432 Beadon K, Beckley R, Beveridge A, Bewley KR, Bijker EM, Blackwell L, Blundell CL, 433 Bolam E, Boland E, Borthwick N, Boyd A, Brenner T, Brown P, Brown-O'Sullivan C, Brunt 434 E, Burbage J, Buttigieg KR, Byard N, Cabrera Puig I, Camara S, Cao M, Cappuccini F, Carr 435 M, Carroll MW, Chadwick J, Chelysheva I, Cho J-S, Cifuentes L, Clark E, Colin-Jones R, 436 Conlon CP, Coombes NS, Cooper R, Crocker WEM, Cunningham CJ, Damratoski BE, 437 Datoo MS, Datta C, Davies H, Demissie T, Di Maso C, DiTirro D, Dong T, Donnellan FR, 438 Douglas N, Downing C, Drake J, Drake-Brockman R, Drury RE, Dunachie SJ, Muhanna OE, 439 Elias SC, Elmore MJ, Emary KRW, English MR, Felle S, Feng S, Da Silva CF, Field S, 440 Fisher R, Ford KJ, Fowler J, Francis E, Frater J, Furze J, Galian-Rubio P, Garlant H, Godwin 441 K, Gorini G, Gracie L, Gupta G, Hamilton E, Hamlyn J, Hanumunthadu B, Harris SA, 442 Harrison D, Hart TC, Hawkins S, Henry JA, Hodges G, Hodgson SHC, Hou MM, Howe E, 443 Howell N, Huang B, Humphries H, Iveson P, Jackson S, Jackson F, Jauregui S, Jeffery K, 444 Jones E, Jones K, Kailath R, Keen J, Kelly S, Kelly D, Kelly E, Kerr D, Khan L, Khozoee B, 445 Killen A, Kinch J, King TB, King L, Kingham-Page L, Klenerman P, Knight JC, Knott D, 446 Koleva S, Larkworthy CW, Larwood JPJ, Lees EA, Lelliott A, Leung S, Li Y, Lias AM, 447 Lipworth S, Liu S, Loew L, Lopez Ramon R, Mallett G, Mansatta K, Marchevsky NG, 448 Marinou S, Marlow E, Marshall JL, Matthews P, McEwan J, McGlashan J, McInroy L, 449 Meddaugh G, Mentzer AJ, Mirtorabi N, Morey E, Morgans R, Morris SJ, Morrison H, 450 Morshead G, Morter R, Moya N, Mukhopadhyay E, Muller J, Munro C, Murphy S, Mweu P, 451 Noé A, Nugent FL, Nuthall E, O'Brien K, O'Connor D, O'Donnell D, Oguti B, Olchawski V, 452 Oliveria C, O'Reilly PJ, Osborne P, Owino N, Parker K, Parracho H, Patrick-Smith M, Peng 453 Y, Penn E, Peralta Alvarez MP, Perring J, Petropoulos C, Pfafferott K, Pipini D, Phillips D, 454 Proud P, Provstgaard-Morys S, Pulido D, Radia K, Rajapaksa D, Ramos Lopez F, Ratcliffe 455 H, Rawlinson T, Pabon ER, Rhead S, Ritchie AJ, Roberts H, Roche S, Rudiansyah I, 456 Salvador S, Sanders H, Sanders K, Satti I, Schmid A, Schofield E, Screaton G, Sedik C, 457 Shaik I, Sharpe HR, Shea A, Silk S, Silva-Reyes L, Skelly DT, Smith CC, Smith DJ, Spencer

458 AJ, Stafford E, Szigeti A, Tahiri-Alaoui A, Tanner R, Taylor IJ, Taylor K, te Water Naude R, 459 Themistocleous Y, Themistocleous A, Thomas M, Thomas TM, Thompson A, Tinh L, Tomic 460 A, Tonks S, Towner J, Tran N, Tree JA, Truby A, Turner C, Turner N, Ulaszewska M, 461 Varughese R, Vichos I, Walker L, Wand M, White C, White R, Williams P, Worth AT, the 462 Oxford CVTG (2020) Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a 463 booster dose induces multifunctional antibody responses. Nature Medicine 464 [5] Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, 465 McCullough MP, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott A, Flach 466 B, Doria-Rose NA, Corbett KS, Morabito KM, O'Dell S, Schmidt SD, Swanson PA, 2nd, 467 Padilla M, Mascola JR, Neuzil KM, Bennett H, Sun W, Peters E, Makowski M, Albert J, Cross K, Buchanan W, Pikaart-Tautges R, Ledgerwood JE, Graham BS, Beigel JH (2020) An 468 469 mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med 383 (20):1920-470 1931 471 [6] Centers for Disease Control and Prevention Chickenpox (Varicella): Interpreting 472 laboratory tests, https://www.cdc.gov/chickenpox/lab-testing/lab-tests.html. Cited January 1, 473 2021 474 [7] Garcia-Beltran WF, Lam EC, Astudillo MG, Yang D, Miller TE, Feldman J, Hauser 475 BM, Caradonna TM, Clayton KL, Nitido AD, Murali MR, Alter G, Charles RC, Dighe A, 476 Branda JA, Lennerz JK, Lingwood D, Schmidt AG, Iafrate AJ, Balazs AB (2021) COVID-477 19-neutralizing antibodies predict disease severity and survival. Cell 184 (2):476-488.e411 478 [8] Addetia A, Crawford KH, Dingens A, Zhu H, Roychoudhury P, Huang M-L, Jerome 479 KR, Bloom JD, Greninger AL (2020) Neutralizing antibodies correlate with protection from 480 SARS-CoV-2 in humans during a fishery vessel outbreak with high attack rate. Journal of 481 Clinical Microbiology 482 [9] Hassan AO, Case JB, Winkler ES, Thackray LB, Kafai NM, Bailey AL, McCune BT, 483 Fox JM, Chen RE, Alsoussi WB (2020) A SARS-CoV-2 infection model in mice 484 demonstrates protection by neutralizing antibodies. Cell 182 (3):744-753. e744 485 Yu J, Tostanoski LH, Peter L, Mercado NB, McMahan K, Mahrokhian SH, Nkolola [10] 486 JP, Liu J, Li Z, Chandrashekar A, Martinez DR, Loos C, Atyeo C, Fischinger S, Burke JS, 487 Slein MD, Chen Y, Zuiani A, Lelis FJN, Travers M, Habibi S, Pessaint L, Van Ry A, Blade 488 K, Brown R, Cook A, Finneyfrock B, Dodson A, Teow E, Velasco J, Zahn R, Wegmann F, 489 Bondzie EA, Dagotto G, Gebre MS, He X, Jacob-Dolan C, Kirilova M, Kordana N, Lin Z, 490 Maxfield LF, Nampanya F, Nityanandam R, Ventura JD, Wan H, Cai Y, Chen B, Schmidt 491 AG, Wesemann DR, Baric RS, Alter G, Andersen H, Lewis MG, Barouch DH (2020) DNA 492 vaccine protection against SARS-CoV-2 in rhesus macaques. Science (New York, NY) 369 493 (6505):806-811 494 Plotkin SA (2010) Correlates of protection induced by vaccination. Clin Vaccine [11] 495 Immunol 17 (7):1055-1065 496 Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector [12] 497 SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, 498 Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, 499 Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng 500 W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T (2020) Efficacy and Safety of the mRNA-501 1273 SARS-CoV-2 Vaccine. New England Journal of Medicine 502 Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez [13] 503 Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, 504 Kalina WV, Cooper D, Frenck RW, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, 505 Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC (2020) Safety and 506 Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine 383 507 (27):2603-2615

508 Sahin U, Muik A, Vogler I, Derhovanessian E, Kranz LM, Vormehr M, Quandt J, [14] 509 Bidmon N, Ulges A, Baum A, Pascal K, Maurus D, Brachtendorf S, Lörks V, Sikorski J, 510 Koch P, Hilker R, Becker D, Eller A-K, Grützner J, Tonigold M, Boesler C, Rosenbaum C, 511 Heesen L, Kühnle M-C, Poran A, Dong JZ, Luxemburger U, Kemmer-Brück A, Langer D, 512 Bexon M, Bolte S, Palanche T, Schultz A, Baumann S, Mahiny AJ, Boros G, Reinholz J, 513 Szabó GT, Karikó K, Shi P-Y, Fontes-Garfias C, Perez JL, Cutler M, Cooper D, Kyratsous 514 CA, Dormitzer PR, Jansen KU, Türeci Ö (2020) BNT162b2 induces SARS-CoV-2-515 neutralising antibodies and T cells in humans. medRxiv:2020.2012.2009.20245175 516 Roche Roche partners with Moderna to include SARS-CoV-2 antibody test in [15] 517 ongoing COVID-19 vaccine trials, https://www.roche.com/media/releases/med-cor-2020-12-518 09.htm. Cited January 17, 2021 519 Widge AT, Rouphael NG, Jackson LA, Anderson EJ, Roberts PC, Makhene M, [16] 520 Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott AB, Flach B, Lin BC, 521 Doria-Rose NA, O'Dell S, Schmidt SD, Neuzil KM, Bennett H, Leav B, Makowski M, 522 Albert J, Cross K, Edara V-V, Floyd K, Suthar MS, Buchanan W, Luke CJ, Ledgerwood JE, 523 Mascola JR, Graham BS, Beigel JH (2020) Durability of Responses after SARS-CoV-2 524 mRNA-1273 Vaccination. New England Journal of Medicine 384 (1):80-82 525 [17] Government of Alberta COVID-19 vaccine distribution, 526 https://www.alberta.ca/covid19-vaccine.aspx. Cited February 4, 2021 527 [18] Abbott SARS-CoV-2 Immunoassays, 528 https://www.corelaboratory.abbott/int/en/offerings/segments/infectious-disease/sars-cov-2. 529 Cited February 21, 2021 530 DiaSorin Liaison(R) SARS-CoV-2 TrimericS IgG Aassay, [19] 531 https://www.diasorin.com/sites/default/files/allegati prodotti/liaisonr sars-cov-532 2\_trimerics\_igg\_assay\_m0870004408.pdf. Cited February 21, 2021 533 GenScript SARS-CoV-2 surrogate virus neutralization test (sVNT) kit, [20] 534 https://www.genscript.com/covid-19-detection-svnt.html. Cited February 21, 2021 535 [21] Taylor SC, Hurst B, Charlton CL, Bailey A, Kanji JN, McCarthy MK, Morrison TE, 536 Huey L, Annen K, DomBourian MG, Knight V (2021) A New SARS CoV-2 Dual Purpose 537 Serology Test: Highly Accurate Infection Tracing and Neutralizing Antibody Response 538 Detection. J Clin Microbiol 539 [22] Rogers TF, Zhao F, Huang D, Beutler N, Burns A, He WT, Limbo O, Smith C, Song 540 G, Woehl J, Yang L, Abbott RK, Callaghan S, Garcia E, Hurtado J, Parren M, Peng L, 541 Ramirez S, Ricketts J, Ricciardi MJ, Rawlings SA, Wu NC, Yuan M, Smith DM, Nemazee 542 D, Teijaro JR, Voss JE, Wilson IA, Andrabi R, Briney B, Landais E, Sok D, Jardine JG, 543 Burton DR (2020) Isolation of potent SARS-CoV-2 neutralizing antibodies and protection 544 from disease in a small animal model. Science 369 (6506):956-963 545 [23] Prendecki M, Clarke C, Brown J, Cox A, Gleeson S, Guckian M, Randell P, Pria AD, 546 Lightstone L, Xu X-N, Barclay W, McAdoo SP, Kelleher P, Willicombe M Effect of 547 previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 548 vaccine. The Lancet 549 Manisty C, Otter AD, Treibel TA, McKnight Á, Altmann DM, Brooks T, [24] 550 Noursadeghi M, Boyton RJ, Semper A, Moon JC (2021) Antibody response to first 551 BNT162b2 dose in previously SARS-CoV-2-infected individuals. Lancet 552 Kempster SL, Almond N, Dimech W, Grangeot-Keros L, Huzly D, Icenogle J, El [25] 553 Mubarak HS, Mulders MN, Nübling CM (2020) WHO international standard for anti-rubella: 554 learning from its application. Lancet Infect Dis 20 (1):e17-e19 555 Andrew MK, McElhaney JE (2020) Age and frailty in COVID-19 vaccine [26]

556 development. The Lancet 396 (10267):1942-1944

557 [27] Spradling PR, Xing J, Williams R, Masunu-Faleafaga Y, Dulski T, Mahamud A, 558 Drobeniuc J, Teshale EH (2013) Immunity to hepatitis B virus (HBV) infection two decades 559 after implementation of universal infant HBV vaccination: association of detectable residual 560 antibodies and response to a single HBV challenge dose. Clin Vaccine Immunol 20 (4):559-561 561 [28] 562 Greub G, Zysset F, Genton B, Spertini F, Frei PC (2001) Absence of anti-hepatitis B 563 surface antibody after vaccination does not necessarily mean absence of immune response. 564 Med Microbiol Immunol 189 (3):165-168 565 Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, Musser BJ, Soo [29] 566 Y, Rofail D, Im J (2021) REGN-COV2, a neutralizing antibody cocktail, in outpatients with 567 Covid-19. New England Journal of Medicine 384 (3):238-251 568 Perera RAPM, Ko R, Tsang OTY, Hui DSC, Kwan MYM, Brackman CJ, To EMW, [30] 569 Yen H-I, Leung K, Cheng SMS, Chan KH, Chan KCK, Li K-C, Saif L, Barrs VR, Wu JT, Sit 570 THC, Poon LLM, Peiris M (2020) Evaluation of a SARS-CoV-2 surrogate virus 571 neutralization test for detection of antibody in human, canine, cat and hamster sera. Journal of 572 Clinical Microbiology: JCM.02504-02520 573 Tan CW, Chia WN, Qin X, Liu P, Chen MIC, Tiu C, Hu Z, Chen VC-W, Young BE, [31] 574 Sia WR, Tan Y-J, Foo R, Yi Y, Lye DC, Anderson DE, Wang L-F (2020) A SARS-CoV-2 575 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike 576 protein-protein interaction. Nature Biotechnology 38 (9):1073-1078 577 [32] Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann AJ, 578 Cornaby C, Bartelt L, Weiss S, Park Y, Edwards CE, Weimer E, Scherer EM, Rouphael N, 579 Edupuganti S, Weiskopf D, Tse LV, Hou YJ, Margolis D, Sette A, Collins MH, Schmitz J, 580 Baric RS, de Silva AM (2020) The receptor-binding domain of the viral spike protein is an 581 immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Science 582 Immunology 5 (48):eabc8413 583 [33] Amit S, Regev-Yochay G, Afek A, Kreiss Y, Leshem E Early rate reductions of 584 SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. The Lancet 585 [34] Pawlowski C, Lenehan P, Puranik A, Agarwal V, Venkatakrishnan A, Niesen MJ, O 586 Horo JC, Badley AD, Halamka J, Soundararajan V (2021) FDA-authorized COVID-19 587 vaccines are effective per real-world evidence synthesized across a multi-state health system. 588 medRxiv:2021.2002.2015.21251623 589 Bruni M, Cecatiello V, Diaz-Basabe A, Lattanzi G, Mileti E, Monzani S, Pirovano L, [35] 590 Rizzelli F, Visintin C, Bonizzi G, Giani M, Lavitrano M, Faravelli S, Forneris F, Caprioli F, 591 Pelicci PG, Natoli G, Pasqualato S, Mapelli M, Facciotti F (2020) Persistence of Anti-SARS-592 CoV-2 Antibodies in Non-Hospitalized COVID-19 Convalescent Health Care Workers. J 593 Clin Med 9 (10) 594 [36] Muecksch F, Wise H, Batchelor B, Squires M, Semple E, Richardson C, McGuire J, 595 Clearly S, Furrie E, Greig N, Hay G, Templeton K, Lorenzi JCC, Hatziioannou T, Jenks S, 596 Bieniasz PD (2021) Longitudinal Serological Analysis and Neutralizing Antibody Levels in 597 Coronavirus Disease 2019 Convalescent Patients. J Infect Dis 223 (3):389-398 598 [37] Mai HK, Trieu NB, Long TH, Thanh HT, Luong ND, Huy LX, Nguyet LA, Man 599 DNH, Anderson DE, Thanh TT, Chau NVV, Thwaites G, Wang LF, Van Tan L, Hung DT 600 (2021) Long-Term Humoral Immune Response in Persons with Asymptomatic or Mild 601 SARS-CoV-2 Infection, Vietnam. Emerg Infect Dis 27 (2):663-666 602 [38] Government of Canada National Advisory Committee on Immunization (NACI): 603 Recommendations on the use of COVID-19 vaccines, https://www.canada.ca/en/public-604 health/services/immunization/national-advisory-committee-on-immunization-605 naci/recommendations-use-covid-19-vaccines.html. Cited March 5, 2021

- 606 [39] Centers for Disease Control and Prevention Vaccine Recommendations and
- 607 Guidelines of the Advisory Committee on Immunization Practices (ACIP): COVID-19 ACIP
- Vaccine Recommendations, <u>https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/covid-</u>
   19.html. Cited March 5, 2021
- 610 [40] Krammer F, Srivastava K, Simon V (2021) Robust spike antibody responses and
- 611 increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2
- 612 mRNA vaccine. medRxiv:2021.2001.2029.21250653
- 613 [41] Saadat S, Tehrani ZR, Logue J, Newman M, Frieman MB, Harris AD, Sajadi MM
- 614 (2021) Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health
- 615 Care Workers Previously Infected With SARS-CoV-2. JAMA
- 616 [42] British Broadcasting Corporation (BBC) Covid: France says just one jab needed for
- 617 previously infected, <u>https://www.bbc.com/news/world-europe-56048444</u>. Cited February 25,
- 618 2021
- 619

N (%) Median Age (years; IQR)	225 (100) 41 (31-55)	group 177 (78.7)	group 48 (21.3)	
	· · ·	177 (78.7)	48 (21.3)	
Median Age (years: IOP)	41 (31-55)			
$Madian \Lambda \sigma (vaare   I ) R$	41 (31-55)	27 (20, 40)		0.001
Wedian Age (years, IQK)		37 (30-48)	84 (75.5-90.5)	< 0.001
Gender (%)				0.11
Male	55 (24.4)	39 (22.0)	16 (33.3)	0.11
Female	170 (75.6)	138 (78.0)	32 (66.7)	
remate	170 (73.0)	138 (78.0)	52 (00.7)	
Time between dose 1 and dose 2 of vaccine (days)				
Median (IQR)	26 (25-27)	26 (25-28)	25 (24-26)	< 0.001
	22 (2.2)		16 (22.2)	.0.001
Recovered from COVID-19 Of these:	22 (9.8)	6 (3.4)	16 (33.3)	< 0.001
	20 (00 0)	1 ((( 7)	16 (100)	0.02
COVID-19 occurred prior to first vaccine dose (%)	20 (90.9)	4 (66.7)	16 (100)	0.02
Time from COVID-19	45	45.5	43	0.54
diagnosis to first vaccine	(30.5-73)	(36-82)	(30.5-73)	0.54
dose (median, range, days)	(50.5-75)	(30-02)	(50.5-75)	
COVID-19 occurred after	2 (0.9)	2 (33.3)	0	_
first vaccine dose (%)	2 (0.5)	2 (00.0)	Ŭ	
Time from first dose to	20.5 (7-34)	20.5 (7-34)	0	_
COVID-19 diagnosis			-	
(range, days)				
Any Co-Morbidity or	45 (20.0)	9 (5.1)	36 (75.0)	< 0.001
Immunosuppression (%)	~ /			
Cardiac Disease (%)	27 (12.0)	0	27 (46.3)	< 0.001
Diabetes (%)	12 (5.3)	3 (1.7)	9 (18.8)	< 0.001
Solid Cancer (%)	5 (2.2)	1 (0.56)	4 (8.3)	0.008
Hematological Cancer (%)	1 (0.44)	1 (0.56)	0	1.00
Asthma (%)	1 (0.44)	1 (0.56)	0	1.00
Renal Disease (%)	5 (2.2)	0	5 (10.4)	< 0.001
COPD (%)	8 (3.6)	0	8 (16.7)	< 0.001
Dementia (%)	22 (9.8)	0	22 (45.8)	< 0.001
Transplant (%)	0	0	0	
Biologic or	5 (2.2)	4 (2.3)	1 (2.1)	1.00
immunosuppressant use <sup>b</sup>				
(%)				
Pregnant (%)	0	0	0	

# **Table 1.** Demographics by type of vaccine administered.

Abbreviations: COPD – chronic obstructive pulmonary disease; IQR – interquartile range <sup>a</sup> p-value comparing BNT162b2 and mRNA-1273; calculated by Mann-Whitney test for age, time between vaccine dosese and time from COVID-19 diagnosis to first vaccine variables, and chi-square or Fisher's exact test for remaining variables.

<sup>b</sup> Between both groups, five participants were considered immunosuppressed. In the BNT162b2 group, four participants were using biologics (adalimumab, daratumumab/bortezomib, dupilumab, infliximab) for ankylosing spondylitis (n=1), relapsed/refractory multiple myeloma (n=1), atopic dermatitis (n=1), and inflammatory bowel disease (n=1). One participant in the mRNA-1273 group used methotrexate for rheumatoid arthritis. Dupilumab is considered to have a low potential for immunosuppression.

Group	Blood sample	Quantitative titers <sup>a</sup>				
	timepoint					
	•	RBD IgG	Trimeric S	nAb Titer		
		Titer	IgG Titer	(ng/mL)		
		(AU/mL)	(AU/mL) <sup>c</sup>	_		
BNT162b2	Baseline	0 <sup>b</sup>	1.85 <sup>b</sup>	$0^{\mathrm{b}}$		
		(0-1296.6)	(1.85-176)	(0-1634.7)		
	2-weeks	653.3	166	355.7		
		(300.4-	(82.6-272)	(161.6-		
		1497.5)		567.5)		
	Pre-2 <sup>nd</sup> dose	1180	195	628.6		
		(687	(138-318.5)	(397-954.6)		
		2135.2)				
mRNA-1273	2-weeks	157.7	27.6	85.6		
		(22.6-	(2.1-235.5)	(0-462.4)		
		4083.5)				
	Pre-2 <sup>nd</sup> dose	557.3	112	381.1		
		(167.9-	(34.5-764)	(11.9-		
		8210.6)		8802.8)		
P-values						
BNT162b2 <sup>d</sup>	Baseline vs.	< 0.0001	< 0.0001	< 0.0001		
	2 weeks					
	2 weeks vs.	< 0.0001	< 0.05	< 0.0001		
	Pre-2 <sup>nd</sup> dose					
mRNA-1273	2 weeks vs	0.06	< 0.01	< 0.05		
	Pre-2 <sup>nd</sup> dose					


**Table 2.** Quantitative titers of testing using commercial assays.

<sup>a</sup>Expressed as median value (IQR), except for BNT162b2 baseline samples.

<sup>b</sup>Expressed as median value (range) due to low numbers of positive samples.

<sup>c</sup>According to product insert, titers <13 AU/mL (negative) and  $\geq$ 13 AU/mL (positive).

<sup>d</sup>All p-values comparing baseline to pre-2nd dose for the BNT162b2 vaccine <0.0001, except for Nucleocapsid IgG where p-value=1.0; NS= Not Significant.



■Nucelocapsid IgG ■RBD IgG ■Trimeric S IgG ■nAb


**Figure 1.** Positivity rates of each assay tested for each group at different time points. Positivity rates are presented in (%).

<sup>a</sup>Baseline versus 2 weeks comparison (BNT162b2): p=NS (Nucleocapsid IgG); p<0.0001 (RBD IgG, Trimeric S IgG, and nAb assays).


<sup>b</sup>2-week versus pre-2<sup>nd</sup> dose comparison (BNT162b2): p=NS for all assays.


<sup>c</sup>All p-values comparing baseline to pre-2<sup>nd</sup> dose (BNT162b2) vaccine were <0.0001, except for nucleocapsid IgG (p=1.0).

<sup>d</sup>2-weeks versus pre-2<sup>nd</sup> dose comparison (mRNA-1273): p=NS (Nucleocapsid IgG); p<0.01 (RBD IgG); p<0.05 (Trimeric S IgG and nAb assays).





b











**Figure 2.** Quantitative testing results from time of first vaccine dose for each vaccine group using the nAb assay (panels a and b); Trimeric S IgG assay (panel c); and RBD IgG assay (panels d and e). Panel (b) presents panel (a) results with y-axis limited to maximum titer of 6000 ng/mL. Panel (e) presents panel (d) results with a shortened y-axis (max titer 5000 AU/mL).